Allergic Asthma - Pipeline Review, H1 2016 - Product Image

Allergic Asthma - Pipeline Review, H1 2016

  • ID: 3643169
  • Report
  • 182 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ALK-Abello A/S
  • Baxalta Incorporated
  • Fountain Biopharma Inc.
  • Kineta, Inc.
  • NeoPharm Co., Ltd.
  • Peptinnovate Limited
  • MORE
Allergic Asthma - Pipeline Review, H1 2016

Summary

The report ‘Allergic Asthma - Pipeline Review, H1 2016’, provides an overview of the Allergic Asthma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
- The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects
- The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Allergic Asthma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ALK-Abello A/S
  • Baxalta Incorporated
  • Fountain Biopharma Inc.
  • Kineta, Inc.
  • NeoPharm Co., Ltd.
  • Peptinnovate Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Allergic Asthma Overview

Therapeutics Development

Pipeline Products for Allergic Asthma - Overview

Pipeline Products for Allergic Asthma - Comparative Analysis

Allergic Asthma - Therapeutics under Development by Companies

Allergic Asthma - Therapeutics under Investigation by Universities/Institutes

Allergic Asthma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Allergic Asthma - Products under Development by Companies

Allergic Asthma - Products under Investigation by Universities/Institutes

Allergic Asthma - Companies Involved in Therapeutics Development

ALK-Abello A/S

Allergopharma GmbH & Co. KG

Amgen Inc.

Aquinox Pharmaceuticals Inc.

ASIT biotech s.a.

Aslan Pharmaceuticals Pte. Ltd.

Axikin Pharmaceuticals, Inc.

Baxalta Incorporated

Chiesi Farmaceutici SpA

Circassia Pharmaceuticals Plc

CSL Limited

Fountain Biopharma Inc.

GlaxoSmithKline Plc

Hydra Biosciences, Inc.

Infinity Pharmaceuticals, Inc.

Kineta, Inc.

Mabtech Limited

Marinomed Biotechnologie GmbH

Mycenax Biotech Inc.

NeoPharm Co., Ltd.

Oxagen Limited

Panacea Biotec Limited

Peptinnovate Limited

Pharmaxis Limited

Protectimmun GmbH

Stallergenes SAS

sterna biologicals Gmbh & Co KG

Swecure AB

The International Biotechnology Center (IBC) Generium

Verona Pharma Plc

Allergic Asthma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AcTMP-1 - Drug Profile

AMG-282 - Drug Profile

AQX-1125 - Drug Profile

Arabinogalactan - Drug Profile

ASLAN-004 - Drug Profile

ASM-8 - Drug Profile

AXP-1275 - Drug Profile

beta-escin - Drug Profile

CHF-6001 - Drug Profile

CSL-311 - Drug Profile

dalazatide - Drug Profile

Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile

duvelisib - Drug Profile

EP-67 - Drug Profile

FB-825 - Drug Profile

GNR-044 - Drug Profile

GSK-2245035 - Drug Profile

hdm-ASIT - Drug Profile

HX-100 - Drug Profile

Lactococcus lactis G121 - Drug Profile

Leukothera - Drug Profile

OC-000459 - Drug Profile

OC-2417 - Drug Profile

omalizumab biosimilar - Drug Profile

omalizumab biosimilar - Drug Profile

omalizumab biosimilar - Drug Profile

omalizumab biosimilar - Drug Profile

omalizumab biosimilar - Drug Profile

omalizumab biosimilar - Drug Profile

OND-86 - Drug Profile

pemirolast potassium - Drug Profile

pentosan polysulfate sodium - Drug Profile

PIN-201601 - Drug Profile

RPL-554 - Drug Profile

S-1226 - Drug Profile

SB-010 - Drug Profile

SG-100 - Drug Profile

SM-301 - Drug Profile

Small Molecule for Allergic Asthma - Drug Profile

Small Molecules for Allergic Asthma - Drug Profile

Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile

standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile

SWE-01 - Drug Profile

tezepelumab - Drug Profile

Vaccine for Allergic Rhinitis and Allergic Asthma - Drug Profile

Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile

Allergic Asthma - Recent Pipeline Updates

Allergic Asthma - Dormant Projects

Allergic Asthma - Discontinued Products

Allergic Asthma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Allergic Asthma, H1 2016

Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H1 2016

Allergic Asthma - Pipeline by ALK-Abello A/S, H1 2016

Allergic Asthma - Pipeline by Allergopharma GmbH & Co. KG, H1 2016

Allergic Asthma - Pipeline by Amgen Inc., H1 2016

Allergic Asthma - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016

Allergic Asthma - Pipeline by ASIT biotech s.a., H1 2016

Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016

Allergic Asthma - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016

Allergic Asthma - Pipeline by Baxalta Incorporated, H1 2016

Allergic Asthma - Pipeline by Chiesi Farmaceutici SpA, H1 2016

Allergic Asthma - Pipeline by Circassia Pharmaceuticals Plc, H1 2016

Allergic Asthma - Pipeline by CSL Limited, H1 2016

Allergic Asthma - Pipeline by Fountain Biopharma Inc., H1 2016

Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H1 2016

Allergic Asthma - Pipeline by Hydra Biosciences, Inc., H1 2016

Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016

Allergic Asthma - Pipeline by Kineta, Inc., H1 2016

Allergic Asthma - Pipeline by Mabtech Limited, H1 2016

Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H1 2016

Allergic Asthma - Pipeline by Mycenax Biotech Inc., H1 2016

Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H1 2016

Allergic Asthma - Pipeline by Oxagen Limited, H1 2016

Allergic Asthma - Pipeline by Panacea Biotec Limited, H1 2016

Allergic Asthma - Pipeline by Peptinnovate Limited, H1 2016

Allergic Asthma - Pipeline by Pharmaxis Limited, H1 2016

Allergic Asthma - Pipeline by Protectimmun GmbH, H1 2016

Allergic Asthma - Pipeline by Stallergenes SAS, H1 2016

Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016

Allergic Asthma - Pipeline by Swecure AB, H1 2016

Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016

Allergic Asthma - Pipeline by Verona Pharma Plc, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Allergic Asthma Therapeutics - Recent Pipeline Updates, H1 2016

Allergic Asthma - Dormant Projects, H1 2016

Allergic Asthma - Dormant Projects (Contd..1), H1 2016

Allergic Asthma - Dormant Projects (Contd..2), H1 2016

Allergic Asthma - Dormant Projects (Contd..3), H1 2016

Allergic Asthma - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Allergic Asthma, H1 2016

Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
ALK-Abello A/S
Allergopharma GmbH & Co. KG
Amgen Inc.
Aquinox Pharmaceuticals Inc.
ASIT biotech s.a.
Aslan Pharmaceuticals Pte. Ltd.
Axikin Pharmaceuticals, Inc.
Baxalta Incorporated
Chiesi Farmaceutici SpA
Circassia Pharmaceuticals Plc
CSL Limited
Fountain Biopharma Inc.
GlaxoSmithKline Plc
Hydra Biosciences, Inc.
Infinity Pharmaceuticals, Inc.
Kineta, Inc.
Mabtech Limited
Marinomed Biotechnologie GmbH
Mycenax Biotech Inc.
NeoPharm Co., Ltd.
Oxagen Limited
Panacea Biotec Limited
Peptinnovate Limited
Pharmaxis Limited
Protectimmun GmbH
Stallergenes SAS
sterna biologicals Gmbh & Co KG
Swecure AB
The International Biotechnology Center (IBC) Generium
Verona Pharma Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll